IDT Biologika
Dedicated to Contract Development and Manufacturing of
Viral Vaccines, Viral Vectors and Biologics

Learn how IDT Biologika is responding to the COVID-19 outbreak

Contract Development and Manufacturing of Viral Vaccines, Viral Vectors and Biologics

IDT Biologika specializes in the contract development and manufacturing of Viral Vaccines, Gene and Immunotherapeutics as well as sterile liquids and lyophilized Biologics. We help biopharmaceutical and biotech companies as well as the US government as part of research consortia with the challenging and complex process of translating viral vaccines and biopharmaceuticals from the research lab through clinical development to large-scale commercial manufacturing inculding drug substance production, fill & finish, packaging and analytics. IDT Biologika provides fully integrated services for GMP compliant end-to-end services in BSL2 facilites meeting EMA, FDA and ANVISA standards.

We strive for strong, trusting and enduring customer partnerships. Our almost 100 year tradition in manufacturing vaccines and biopharmaceuticals motivates and obligates us to advance our clients’ products to prevent and treat diseases that impact the health of people worldwide.

Latest IDT News

SARS-CoV-2: IDT Biologika fills vaccine candidate

Wednesday, 29. July 2020

Clinical phase about to begin more info

Deputy leader of the parliamentary FDP visits IDT Biologika

Friday, 10. July 2020

Battle against SARS-CoV-2 at the heart of Germany more info

Positive interim summary of strategic realignment at CPhl trade fair:

Tuesday, 5. November 2019

IDT Biologika expands portfolio of viral vaccines and biologics more info

IDT Biologika Awarded new Task Order to Manufacture Vaccines and Biologics for Infectious Diseases

Monday, 4. November 2019

IDT Biologika Awarded new Task Order in the Scope of 10-Year NIH Contract to Manufacture Vaccines and Biologics for Infectious Diseases more info

IDT Biologika inaugurates new multifunctional production facility for vaccines at BioPharmaPark area

Friday, 5. July 2019

New building for vaccine production enables even more flexible reaction to customer demands more info

Twitter
@IDT Biologika

Friday, 7. August 2020

IDT Biologika has been awarded the title of the most #innovative company in the #biopharmaceutical sector by Focus… https://t.co/GRDLFreV4O more info

Friday, 31. July 2020

We welcome you to join us on an exciting Virtual Tour through #SaxonyAnhalt, where you will find an impressive ecos… https://t.co/nvMCajkiff more info

Thursday, 30. July 2020

RT @DZIF_: @idtbiologika und das DZIF freuen sich über die angekündigte Förderung ihres Impfstoffprojekts. https://t.co/5B9JCinJBW https:/… more info

Wednesday, 29. July 2020

We filled the 2nd clinical batch of the newly-developed #vaccine candidate against the #coronavirus SARS-CoV-2. “W… https://t.co/M3bMskGAUe more info

Monday, 27. July 2020

In response to the increased production for COVID-19 #vaccines worldwide, IDT Biologika is providing capacity to As… https://t.co/9DRqW9UrDo more info

Thursday, 23. July 2020

Prime Ministers Dr. Reiner Haseloff and Winfried Kretschmann paid a visit to IDT Biologika. The guests were welcome… https://t.co/T0PpFDHOt1 more info

Tuesday, 21. July 2020

RT @sachsenanhalt: Besuch bei @idtbiologika in Deassau-Roßlau. Hier wird in Zusammenarbeit mit dem Deutschen Zentrum für Infektionsforschun… more info

Wednesday, 15. July 2020

In the fight against the pandemic SARS-CoV-2 IDT is turning to national cooperation, international interaction and… https://t.co/REIKvaaNU5 more info

Wednesday, 8. July 2020

IDT Biologika has specialized in #vaccines to fight infectious diseases and is now involved in #COVID-19 vaccine pr… https://t.co/p0e75lrDF5 more info